NEW
Stock Screener with Intrinsic Value
Novo Nordisk A/S (NVO)
Last Price$86.30.8%
Market Cap$384.7B
LTM EPS
DKK 21.25
EPS growth
145.4%
Ben Graham Fair Value
$814.2
Undervalued (Ben Graham formula)
843.4%
Stock quality
7/10
Good
NVO Ben Graham Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVO EPS growth & Dividend Yield
Crunching data... Almost there!
NVO vs Peer Set: Ben Graham Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVO
Peter Lynch Fair Value
Reverse DCF
Earnings growth model
Earnings Power Value
Discount rate
Relative Value
Intrinsic Value
Margin of safety
DCF value calculator
Peter Lynch charts
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Novo Nordisk A/S's fair value according to the Ben Graham formula?
As of Sep 30, 2024, Novo Nordisk A/S's fair value using the Ben Graham formula is $814.2 per share. This is calculated using Ben Graham formula, where EPS is DKK 21.3 and BVPS (Book Value Per Share) is DKK 27.0. The current price of $86.3 suggests Novo Nordisk A/S may be overvalued by this conservative metric.
What is Novo Nordisk A/S earnings per share (EPS)?
Novo Nordisk A/S earnings per share (EPS) for the twelve months ending Sep 30, 2024, was DKK 21.3, a 145.4% growth year-over-year.
What is Novo Nordisk A/S's margin of safety based on the Ben Graham analysis?
Novo Nordisk A/S's margin of safety is positive 843.4%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.